Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
ESTRADERM is a transdermal estradiol delivery system approved in 1986 for hormone replacement therapy and related estrogen-deficiency indications. The patch delivers estradiol directly through the skin, bypassing first-pass hepatic metabolism and providing steady-state hormone levels. This small-molecule formulation represents a foundational approach to hormone replacement in women's health.
Product is in late-stage lifecycle with moderate competitive pressure (30/100); team size and hiring likely constrained as patent expiration approaches.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ESTRADERM offers exposure to a legacy hormone replacement franchise with deep market penetration but declining career momentum due to LOE approaching. Roles focus on defending market share, managing generic/authorized generic transitions, and maximizing profitability in a mature portfolio segment.
Worked on ESTRADERM at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.